Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies
O'Brien, Neil A, Huang, Holly K T, McDermott, Martina S J, Madrid, Athena M, Luo, Tong, Ayala, Raul, Issakhanian, Shawnt, Gong, Ke Wei, Lu, Ming, Zhang, Jun, Slamon, Dennis J
Published in Molecular cancer therapeutics (04.05.2022)
Published in Molecular cancer therapeutics (04.05.2022)
Get full text
Journal Article
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers
O'Brien, Neil A, McDermott, Martina S J, Zhang, Jun, Gong, Ke Wei, Lu, Ming, Hoffstrom, Benjamin, Luo, Tong, Ayala, Raul, Chau, Kevin, Liang, Min, Madrid, Athena M, Donahue, Timothy R, Glaspy, John A, Presta, Leonard, Slamon, Dennis J
Published in Molecular cancer therapeutics (01.12.2023)
Published in Molecular cancer therapeutics (01.12.2023)
Get full text
Journal Article
Abstract 1900: TORL-3-600, a novel antibody drug conjugate directed against cadherin 17 (CDH17), has preclinical efficacy in colorectal, gastric, and pancreatic cancer
O'Brien, Neil A., McDermott, Martina SJ, Zhang, Jun, Lu, Ming, Gong, Ke Wei, Hoffstrom, Benjamin, Jia, Wei Ping, Luo, Tong, Madrid, Athena M., Liang, Min, Glaspy, John A., Slamon, Dennis J.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 4044: Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers
O'Brien, Neil A., McDermott, Martina S., O'Boyle, Brendan M., Reeves, Corey M., Bartberger, Michael, Loson, Oliver, Chau, Kevin, Hong, Jenny J., Jia, Weiping, Kamranpour, Naeimeh, Luo, Tong, Ayala, Raul, Madrid, Athena M., Glaspy, John A., Stoltz, Brian M., Slamon, Dennis J.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article